Rakuten Medical and LOTTE Biologics have signed an agreement to boost production of Rakuten Medical’s cancer treatment, Alluminox® photoimmunotherapy. The deal was announced at the J.P. Morgan Healthcare Conference in San Francisco.
Under the agreement, LOTTE Biologics will help manufacture key components, like cancer monoclonal antibodies, for Rakuten Medical's cancer therapy. This support will help with Rakuten Medical’s global clinical trials and future commercial expansion.
Rakuten Medical’s photoimmunotherapy targets cancer cells in solid tumors using a combination of antibodies and light-activated agents. The therapy is already approved in Japan for recurrent head and neck cancer, and a global Phase 3 trial is underway in the U.S., Taiwan, Japan, with plans to expand to Ukraine and Poland. They are also planning a new trial in Japan for other types of solid tumors.
The increased demand for these treatments is driving the need for more production capacity. LOTTE Biologics, with its advanced manufacturing facility in New York, will provide the necessary support to meet the growing global demand and ensure high-quality production.
Rakuten Medical, Inc. is a global biotech company working on developing and bringing to market its Alluminox® photoimmunotherapy, a treatment that has been shown to quickly and selectively destroy cancer cells. Currently, this treatment is still being tested outside Japan. Rakuten Medical’s goal is to fight cancer by developing its innovative treatments and making them available to as many patients as possible around the world. The company has offices in five countries/regions, including the United States (its headquarters), Japan, Taiwan, Switzerland, and India.